Comparing Novabridge Biosciences (NBP) and Its Rivals

Novabridge Biosciences (NASDAQ:NBP) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Novabridge Biosciences to similar businesses based on the strength of its earnings, dividends, analyst recommendations, institutional ownership, profitability, valuation and risk.

Earnings & Valuation

This table compares Novabridge Biosciences and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Novabridge Biosciences	$3.89 million	-$46.27 million	-2.53
Novabridge Biosciences Competitors	$691.14 million	$10.43 million	-15.00

Novabridge Biosciences’ rivals have higher revenue and earnings than Novabridge Biosciences. Novabridge Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Novabridge Biosciences and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novabridge Biosciences	1	0	1	0	2.00
Novabridge Biosciences Competitors	9828	15118	45430	1585	2.54

Novabridge Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 889.55%. As a group, “Biotechnology” companies have a potential upside of 102.47%. Given Novabridge Biosciences’ higher probable upside, equities analysts clearly believe Novabridge Biosciences is more favorable than its rivals.

Profitability

This table compares Novabridge Biosciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novabridge Biosciences	N/A	N/A	N/A
Novabridge Biosciences Competitors	-9,046.59%	-199.78%	-30.61%

Institutional and Insider Ownership

38.4% of Novabridge Biosciences shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 22.1% of Novabridge Biosciences shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Novabridge Biosciences has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Novabridge Biosciences’ rivals have a beta of 1.16, suggesting that their average stock price is 16% more volatile than the S&P 500.

Summary

Novabridge Biosciences beats its rivals on 7 of the 13 factors compared.

Novabridge Biosciences Company Profile

Novabridge Biosciences, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.